Francisco J Torres-Espínola1, Signe Altmäe2, Maria Teresa Segura1, Antonio Jerez3, Tania Anjos1, Maribel Chisaguano4, M Carmen López-Sabater5, Carmen Entrala6, Juan Carlos Alvarez7, Ahmad Agil8, Jesus Florido9, Andres Catena10, Miguel Pérez-García11, Cristina Campoy12. 1. Centre of Excellence for Paediatric Research EURISTIKOS, University of Granada, Granada, Spain. 2. Centre of Excellence for Paediatric Research EURISTIKOS, University of Granada, Granada, Spain; Department of Paediatrics, University of Granada, Granada, Spain. 3. Department of Paediatrics, University of Granada, Granada, Spain. 4. Facultad de Ciencias de la Salud, Universidad Nacional de Chimborazo, Ecuador. 5. Department of Nutrition and Food Science, University of Barcelona, Barcelona, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III, Madrid, Spain. 6. Lorgen G.P., S.L. BIC Granada, PTS, Granada, Spain. 7. Department of Legal Medicine, University of Granada, Granada, Spain. 8. Department of Pharmacology, University of Granada, Granada, Spain. 9. Department of Obstetrics and Gynaecology, University of Granada, Granada, Spain. 10. Department of Experimental Psychology, University of Granada, Granada, Spain; Mind, Brain and Behaviour Research Centre (CIMCYC), University of Granada, Granada, Spain. 11. Mind, Brain and Behaviour Research Centre (CIMCYC), University of Granada, Granada, Spain; Department of Personality, Neuropsychology and Behaviour, University of Granada, Granada, Spain. 12. Centre of Excellence for Paediatric Research EURISTIKOS, University of Granada, Granada, Spain; Department of Paediatrics, University of Granada, Granada, Spain. Electronic address: ccampoy@ugr.es.
Abstract
BACKGROUND: Peroxisome proliferator activated receptors (PPARs) are ligand activated transcription factors with crucial functions in lipid homeostasis, glucose metabolism, anti-inflammatory processes, placental development, and are involved in cognitive functions and neurodegenerative diseases. Polymorphisms in PPAR genes are shown to influence the activity of these receptors. AIMS: 1) To examine the association of PPARG Pro12Ala polymorphism in pregnant women and their offspring on infant's neurodevelopmental outcomes during the first 18 months of life; 2) to determine the influence of Pro12Ala polymorphism on fatty acid concentrations in plasma phospholipids and placental tissue. STUDY DESIGN: 138 mother-infant pairs from the PREOBE observational study were genotyped for PPARG Pro12Ala. Plasma phospholipids and placental fatty acid concentrations were measured at delivery. Infants' neuropsychological assessment at 6 and 18 months of age was performed using Bayley III. RESULTS: The effect of Pro12Ala on infant's neurodevelopmental outcomes was detected at 18 months, but not at 6 months of age. 18 months old infants born to mothers with wild-type Pro12 genotype had better cognitive (OR=5.11, 95% CI: 1.379-18.96, p=0.015), language (OR=3.41, 95% CI: 1.35-11.24, p=0.044), and motor development scores (OR=4.77, 95% CI: 1.243-18.33, p=0.023) than the Ala allele carriers. Pro12Ala variants did not seem to affect fatty acids concentrations in blood nor in placenta at delivery. CONCLUSIONS: Infants born to mothers with Pro12 genotype have better neurodevelopmental outcomes at 18 months of age than Ala allele carriers, indicating a long-term transplacental action of PPARγ variants on foetal brain development.
BACKGROUND: Peroxisome proliferator activated receptors (PPARs) are ligand activated transcription factors with crucial functions in lipid homeostasis, glucose metabolism, anti-inflammatory processes, placental development, and are involved in cognitive functions and neurodegenerative diseases. Polymorphisms in PPAR genes are shown to influence the activity of these receptors. AIMS: 1) To examine the association of PPARGPro12Ala polymorphism in pregnant women and their offspring on infant's neurodevelopmental outcomes during the first 18 months of life; 2) to determine the influence of Pro12Ala polymorphism on fatty acid concentrations in plasma phospholipids and placental tissue. STUDY DESIGN: 138 mother-infant pairs from the PREOBE observational study were genotyped for PPARGPro12Ala. Plasma phospholipids and placental fatty acid concentrations were measured at delivery. Infants' neuropsychological assessment at 6 and 18 months of age was performed using Bayley III. RESULTS: The effect of Pro12Ala on infant's neurodevelopmental outcomes was detected at 18 months, but not at 6 months of age. 18 months old infants born to mothers with wild-type Pro12 genotype had better cognitive (OR=5.11, 95% CI: 1.379-18.96, p=0.015), language (OR=3.41, 95% CI: 1.35-11.24, p=0.044), and motor development scores (OR=4.77, 95% CI: 1.243-18.33, p=0.023) than the Ala allele carriers. Pro12Ala variants did not seem to affect fatty acids concentrations in blood nor in placenta at delivery. CONCLUSIONS:Infants born to mothers with Pro12 genotype have better neurodevelopmental outcomes at 18 months of age than Ala allele carriers, indicating a long-term transplacental action of PPARγ variants on foetal brain development.
Authors: Sarah U Morton; Brian J Leyshon; Eleonora Tamilia; Rutvi Vyas; Michaela Sisitsky; Imran Ladha; John B Lasekan; Matthew J Kuchan; P Ellen Grant; Yangming Ou Journal: Front Psychiatry Date: 2022-06-23 Impact factor: 5.435
Authors: Berthold Hocher; Yong-Ping Lu; Christoph Reichetzeder; Xiaoli Zhang; Oleg Tsuprykov; Jan Rahnenführer; Li Xie; Jian Li; Liang Hu; Bernhard K Krämer; Ahmed A Hasan Journal: Diabetologia Date: 2022-04-30 Impact factor: 10.460
Authors: Staffan K Berglund; Luz García-Valdés; Francisco J Torres-Espinola; M Teresa Segura; Cristina Martínez-Zaldívar; María J Aguilar; Ahmad Agil; Jose A Lorente; Jesús Florido; Carmen Padilla; Signe Altmäe; Acensión Marcos; M Carmen López-Sabater; Cristina Campoy Journal: BMC Public Health Date: 2016-03-01 Impact factor: 3.295